One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Insights from prospective multi-omic profiling of lymphocytes in resected lung cancer
A.Chow12M.D.Hellmann123
Manufacture of adoptive cell therapies at academic cancer centers: scientific, safety and regulatory challenges
K.S.Saini1I.M.Svane2M.Juan3F.Barlesi45F.André6
PET imaging for cancer immunotherapy: the Immuno-PET
A.M.Menzies123S.Lastoria4
Innovation at life’s end: a moment for hope
B.W.Corn12O.Rosengarten12
The enduring decision-making role of the surgeon in the multidisciplinary management of GIST
C.J.Swallow
Gastrointestinal stromal tumours: ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up
P.G.Casali12J.Y.Blay3N.Abecassis4J.Bajpai5S.Bauer6R.Biagini7S.Bielack8S.Bonvalot9I.Boukovinas10J.V.M.G.Bovee11K.Boye12T.Brodowicz13A.Buonadonna14E.De �lava1516A.P.Dei Tos17X.G.Del Muro18A.Dufresne19M.Eriksson20…S.Stacchiotti1
Hesitancy around low-dose CT screening for lung cancer
J.L.Dickson1†C.Horst1†A.Nair12S.Tisi1R.Prendecki1S.M.Janes13
Distinct tumor-infiltrating lymphocyte landscapes are associated with clinical outcomes in localized non-small-cell lung cancer
L.Federico1†D.J.McGrail2†S.-E.Bentebibel3†C.Haymaker4A.Ravelli3M.-A.Forget3T.Karpinets5P.Jiang6A.Reuben6M.V.Negrao6J.Li5R.Khairullah6J.Zhang5A.Weissferdt7A.A.Vaporciyan8M.B.Antonoff8G.Walsh8S.-Y.Lin2…C.Bernatchez3
International Tailored Chemotherapy Adjuvant (ITACA) trial, a phase III multicenter randomized trial comparing adjuvant pharmacogenomic-driven chemotherapy versus standard adjuvant chemotherapy in completely resected stage II-IIIA non-small-cell lung cancer
S.Novello1†V.Torri2†C.Grohe3S.Kurz4M.Serke5T.Wehler5A.Meyer6D.Ladage6M.Geissler7I.Colantonio8C.Cauchi8E.Stoelben9A.Ceribelli10C.Kropf-Sanchen11G.Valmadre12G.Borra13M.Schena14A.Morabito15…G.V.Scagliotti1â€
Consolidation nivolumab and ipilimumab versus observation in limited-disease small-cell lung cancer after chemo-radiotherapy – results from the randomised phase II ETOP/IFCT 4-12 STIMULI trial
S.Peters12†J.-L.Pujol3†§U.Dafni45M.Dómine6¶S.Popat7M.Reck8J.Andrade9¶A.Becker10D.Moro-Sibilot11§A.Curioni-Fontecedro12O.Molinier13§K.Nackaerts14A.Insa Mollá15¶R.Gervais16§G.López Vivanco17¶J.Madelaine18§J.Mazieres19§M.Faehling20…R.Califano
89Zr-pembrolizumab imaging as a non-invasive approach to assess clinical response to PD-1 blockade in cancer
I.C.Kok1J.S.Hooiveld1†P.P.van de Donk1†D.Giesen1E.L.van der Veen2M.N.Lub-de Hooge2A.H.Brouwers3T.J.N.Hiltermann4A.J.van der Wekken4L.B.M.Hijmering-Kappelle4W.Timens5S.G.Elias6G.A.P.Hospers1H.J.M.Groen4W.Uyterlinde7B.van der Hiel8J.B.Haanen7D.J.A.de Groot1…E.G.E.de Vries1
Improved breast cancer histological grading using deep learning
Y.Wang1B.Acs23S.Robertson23B.Liu1L.Solorzano4C.Wählby4J.Hartman235†M.Rantalainen15â€
FDG-PET to predict long-term outcome from anti-PD-1 therapy in metastatic melanoma
Author links open overlay panelF.Dimitriou12S.N.Lo13A.C.Tan45L.Emmett6R.Kapoor7M.S.Carlino18G.V.Long13910A.M.Menzies139
Effects of active cancer treatment on safety and immunogenicity of COVID-19 mRNA-BNT162b2 vaccine: preliminary results from the prospective observational Vax-On study
F.Nelli1A.Fabbri1A.Onorato1D.Giannarelli2M.A.Silvestri3J.R.Giron Berrios1A.Virtuoso1E.Marrucci1C.Signorelli1M.G.Chilelli1F.Primi1M.Schirripa1M.Mazzotta1E.M.Ruggeri1
SARS-CoV-2 vaccine uptake, perspectives, and adverse reactions following vaccination in patients with cancer undergoing treatment
J.C.Figueiredo1U.Ihenacho12N.M.Merin1O.Hamid3J.Darrah1J.Gong1R.Paquette1A.C.Mita1R.Vescio1I.Mehmi1R.Basho1S.J.Salvy1C.H.Shirazipour14N.Caceres1L.J.Finster1B.Coleman5H.U.Arnow5L.Florindez5…K.L.Reckamp1
VP9-2021: ORIENT-31: Phase III study of sintilimab with or without IBI305 plus chemotherapy in patients with EGFR mutated nonsquamous NSCLC who progressed after EGFR-TKI therapy
S.Lu1L.Wu2H.Jian1Y.Cheng3Q.Wang4J.Fang5Z.Wang5Y.Hu6M.Sun7L.Han8L.Miao9C.Ding10J.Cui11B.Li12X.Li13K.Wang14S.Cang15Y.Pan16…A.Liu18
VP10-2021: Cabozantinib (C) plus atezolizumab (A) versus sorafenib (S) as first-line systemic treatment for advanced hepatocellular carcinoma (aHCC): Results from the randomized phase III COSMIC-312 trial
R.K.Kelley1T.Yau2A.-L.Cheng3A.Kaseb4S.Qin5A.X.Zhu6S.Chan7W.Sukeepaisarnjaroen8V.Breder9G.Verset10E.Gane11I.Borbath12J.D.Gomez Rangel13P.Merle14F.M.Benzaghou15K.Banerjee16S.Hazra17J.Fawcett18L.Rimassa19
Corrigendum to ‘Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up’: [Ann Oncol 2021; 32(3): 309-322]
M.A.Dimopoulos1P.Moreau2E.Terpos1M.V.Mateos3S.Zweegman4G.Cook5M.Delforge6R.Hájek7F.Schjesvold89M.Cavo10H.Goldschmidt11T.Facon12H.Einsele13M.Boccadoro14J.San-Miguel15P.Sonneveld16U.Mey17EHA Guidelines Committee ESMO Guidelines Committee
Corrigendum to ‘43P The effect of quercetin and doxorubicin treatment on the proliferative capacity of tumour cells’: [Annals of Oncology Volume 32, Supplement 6, October 2021, Pages S1358-S1359]
D.M.Alexandru1A.M.Coman2M.Crivineanu1A.Busca2M.E.Panait2F.Iordache1
